Per-Olof Edin

Östersjöstiftelsen is a long-term private equity-focused investor. They develop research projects from Södertörn University College and invest in growth-phase firms and value shares on a European basis. They provide capital injection in addition to expertise with developing and expanding firms looking to move beyond the seed and start-up stages. Areas they have invested in include offshore mooring chains and anchors, dermatology pharmaceuticals, pharmaceuticals for the treatment of cancers with non-functional p53, visibility enhancement technology (VET), biosensor systems, radio and information technology, and interstitial photodynamic therapy (PDT) medical devices.

SRK's investment objective is to generate profits for their shareholders. Their venture capital investment strategy focuses on small- and mid-sized distressed firms in Sweden. They concentrate on unlisted firms in the trade and industry sectors. They look for firms with sound core operations yet are underperforming. They target firms with an annual turnover in the range of SEK 40 million to SEK 400 million. SRK invests alone and also considers co-investment possibilities. The firm generally takes at last 25% stakeholder positions. They take an active role in the reconstruction and structuring of their portfolio firms. They seek to add value through timely capital injections and provide professional advice. They take Board positions. The investment time frame spans three to five years before exit.

Functions as a College/University

Provides oral anti-cancer therapies

Operates as a life sciences investment company